Total Payments
$8,077
2024 Payments
$574.60
Companies
35
Transactions
665
Medicare Patients
1,664
Medicare Billing
$237,247
Payment Breakdown by Category
Food & Beverage$8,034 (99.5%)
Education$41.83 (0.5%)
Gifts$1.71 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,034 | 660 | 99.5% |
| Education | $41.83 | 4 | 0.5% |
| Gift | $1.71 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,444 | 168 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,037 | 58 | $0 (2024) |
| PFIZER INC. | $616.15 | 35 | $0 (2024) |
| Janssen Biotech, Inc. | $607.47 | 40 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $556.95 | 31 | $0 (2024) |
| Gilead Sciences, Inc. | $445.00 | 21 | $0 (2023) |
| Romark Laboratories, LC | $389.03 | 165 | $0 (2020) |
| Allergan Inc. | $295.42 | 45 | $0 (2019) |
| Celgene Corporation | $273.51 | 14 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $189.29 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $574.60 | 29 | PFIZER INC. ($203.46) |
| 2023 | $627.91 | 31 | ABBVIE INC. ($189.15) |
| 2022 | $612.08 | 32 | ABBVIE INC. ($144.82) |
| 2021 | $1,246 | 79 | AbbVie Inc. ($374.52) |
| 2020 | $966.75 | 72 | AbbVie Inc. ($312.22) |
| 2019 | $1,746 | 134 | AbbVie, Inc. ($749.10) |
| 2018 | $1,234 | 154 | AbbVie, Inc. ($355.96) |
| 2017 | $1,071 | 134 | AbbVie, Inc. ($270.95) |
All Payment Transactions
665 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Immunology | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Immunology | ||||||
| 10/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/15/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $29.01 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/15/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $2.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/01/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Immunology | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Immunology | ||||||
| 06/20/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/07/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Immunology | ||||||
| 04/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Gastroenterology | ||||||
| 04/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/09/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.11 | General |
| Category: Neuroscience | ||||||
| 03/28/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/22/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 356 | 379 | $213,118 | $40,167 |
| 2022 | 10 | 470 | 503 | $284,275 | $53,771 |
| 2021 | 9 | 433 | 476 | $244,364 | $48,903 |
| 2020 | 11 | 405 | 1,865 | $460,772 | $94,407 |
Total Patients
1,664
Total Services
3,223
Medicare Billing
$237,247
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 56 | 56 | $45,752 | $10,055 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 156 | $29,016 | $9,024 | 31.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 36 | 36 | $39,744 | $7,493 | 18.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 32 | 32 | $33,408 | $4,364 | 13.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 21 | 21 | $17,178 | $3,849 | 22.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 46 | 46 | $41,216 | $3,182 | 7.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $5,460 | $1,672 | 30.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,344 | $526.56 | 39.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 71 | 73 | $80,592 | $14,888 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 162 | 192 | $35,886 | $12,428 | 34.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 38 | 38 | $31,046 | $6,995 | 22.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 32 | 32 | $26,176 | $5,997 | 22.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 44 | 44 | $45,936 | $5,090 | 11.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 55 | 55 | $49,280 | $3,676 | 7.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 21 | $5,733 | $2,069 | 36.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $5,733 | $1,655 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 16 | 16 | $1,792 | $626.02 | 34.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 11 | 11 | $2,101 | $346.55 | 16.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 152 | 184 | $34,224 | $12,110 | 35.4% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 48 | 50 | $55,200 | $10,323 | 18.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 37 | 37 | $30,229 | $7,066 | 23.4% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 40 | 40 | $41,760 | $4,928 | 11.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 51 | $13,923 | $3,941 | 28.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 46 | 48 | $43,008 | $3,830 | 8.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 20 | 20 | $16,360 | $3,829 | 23.4% |
About Dr. Robert Gilbert, MD
Dr. Robert Gilbert, MD is a Gastroenterology healthcare provider based in Land O Lakes, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821103573.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Gilbert, MD has received a total of $8,077 in payments from pharmaceutical and medical device companies, with $574.60 received in 2024. These payments were reported across 665 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($8,034).
As a Medicare-enrolled provider, Gilbert has provided services to 1,664 Medicare beneficiaries, totaling 3,223 services with total Medicare billing of $237,247. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Land O Lakes, FL
- Active Since 08/21/2006
- Last Updated 10/22/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1821103573
Products in Payments
- XIFAXAN (Drug) $951.84
- XELJANZ (Drug) $539.42
- Mavyret (Drug) $534.36
- STELARA (Biological) $468.75
- Humira (Biological) $458.94
- LINZESS (Drug) $387.92
- MAVYRET (Drug) $286.68
- ZEPOSIA (Drug) $246.94
- Alinia Tablets 500mg 30 count bottle (Drug) $228.92
- Entyvio (Biological) $225.67
- HUMIRA (Biological) $220.45
- ENTYVIO (Biological) $216.60
- Creon (Drug) $214.93
- RINVOQ (Biological) $159.20
- Alinia (Drug) $142.35
- Linzess (Drug) $128.96
- CREON (Drug) $124.19
- DIFICID (Drug) $102.60
- TRULANCE (Drug) $99.99
- Amitiza (Drug) $99.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.